Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial

Peradze, Natia; Farr, Olivia M.; Perakakis, Nikolaos; Lázaro, Iolanda; Sala-Vila, Aleix; Mantzoros, Christos S.

doi:10.1186/s12933-019-0945-7

Cardiovascular Diabetology

Table 2 Changes in lipoprotein subclasses after treatment with liraglutide vs. placebo

From: Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial

Lipoprotein subclasses	Placebo			Liraglutide			P¹	P²
Lipoprotein subclasses	Visit 1	Visit 6	Delta changes	Visit 1	Visit 6	Delta changes	P¹	P²
LDL
Concentration of particles of different size
S-LDL-P (× 10⁻⁴)	1.4 ± 0.31	1.47 ± 0.33	0.07 ± 0.04	1.37 ± 0.31	1.28 ± 0.29	− 0.09 ± 0.05	0.01	0.13
M-LDL-P (× 10⁻⁴)	1.2 ± 0.27	1.27 ± 0.28	0.07 ± 0.04	1.18 ± 0.26	1.11 ± 0.25	− 0.08 ± 0.05	0.02	0.15
Concentration of lipids in particles of different size
S-LDL-L	0.39 ± 0.09	0.41 ± 0.09	0.02 ± 0.012	0.39 ± 0.09	0.36 ± 0.081	− 0.03 ± 0.01	0.01	0.01
S-LDL-PL (× 10⁻²)	12.5 ± 2.78	12.9 ± 2.87	0.42 ± 0.25	12.2 ± 2.72	11.6 ± 2.6	− 0.55 ± 0.25	0.01	0.01
S-LDL-FC (× 10⁻²)	7.23 ± 1.61	7.48 ± 1.67	0.25 ± 0.17	7.14 ± 1.6	6.75 ± 1.51	− 0.4 ± 0.2	0.02	0.01
M-LDL-L	0.61 ± 0.14	0.65 ± 0.14	0.03 ± 0.02	0.6 ± 0.14	0.57 ± 0.13	− 0.04 ± 0.02	0.02	0.01
M-LDL-PL	17.3 ± 3.86	18 ± 4.02	0.73 ± 0.4	16.9 ± 3.78	16.2 ± 3.62	− 0.75 ± 0.43	0.01	0.01
Concentration of lipids relative to total lipids in particles of different size
S-LDL-PL_%	31.9 ± 7.12	31.4 ± 7.03	− 0.44 ± 0.44	31.9 ± 7.13	32.6 ± 7.28	0.65 ± 0.5	0.08	0.01
S-LDL-CE_%	43.2 ± 9.68	44 ± 9.85	0.81 ± 0.76	43.3 ± 9.68	42.4 ± 9.49	− 0.89 ± 0.8	0.12	0.02
S-LDL-FC_%	18.5 ± 4.12	18.2 ± 4.07	− 0.26 ± 0.14	18.6 ± 4.17	18.8 ± 4.21	0.19 ± 0.15	0.02	0.002
M-LDL-PL_%	28.4 ± 6.34	28.1 ± 6.28	− 0.29 ± 0.36	28.4 ± 6.35	29 ± 6.48	0.57 ± 0.43	0.11	0.02
M-LDL-CE_%	45 ± 10.1	46 ± 10.3	1 ± 0.7	45 ± 10.1	44.2 ± 9.89	− 0.81 ± 0.82	0.08	0.02
M-LDL-FC_%	19.8 ± 4.43	19.5 ± 4.36	− 0.34 ± 0.17	20 ± 4.48	20.3 ± 4.55	0.3 ± 0.24	0.02	0.002
HDL
Concentration of lipids relative to total lipid concentration in the particles of different size
L-HDL-C_%	44.9 ± 10	43.2 ± 9.63	− 1.52 ± 2.67	45.8 ± 10.2	45 ± 10.1	6.15 ± 3.55	0.03	0.12
L-HDL-CE_%	36.4 ± 8.11	35.2 ± 7.85	− 1.03 ± 2.31	36.6 ± 8.19	36.7 ± 8.21	5.59 ± 3.06	0.02	0.09
XL-HDL-PL_%	43.6 ± 9.82	43.5 ± 9.75	− 2.28 ± 1.88	44.5 ± 9.94	46.3 ± 10.4	1.76 ± 0.97	0.05	0.1
XL-HDL-CE_%	41.5 ± 9.2	42.4 ± 9.44	0.93 ± 0.91	40.6 ± 9.08	39.1 ± 8.75	− 1.43 ± 0.74	0.03	0.08
VLDL
Concentration of particles of different size
XS-VLDL-P (× 10⁻⁴)	0.35 ± 0.08	0.36 ± 0.08	0.016 ± 0.009	0.34 ± 0.08	0.33 ± 0.07	− 0.01 ± 0.01	0.04	0.31
Concentration of lipids in particles of different size
XS-VLDL-L	0.44 ± 0.1	0.46 ± 0.1	0.02 ± 0.01	0.43 ± 0.1	0.42 ± 0.09	− 0.01 ± 0.01	0.04	0.04
XS-VLDL-PL (× 10²)	12.9 ± 2.88	13.5 ± 3.01	0.58 ± 0.39	12.6 ± 2.81	12.1 ± 2.71	− 0.42 ± 0.43	0.06	0.03
S-VLDL-C	17.3 ± 3.88	19.3 ± 4.32	1.98 ± 0.69	17 ± 3.8	17.2 ± 3.85	0.19 ± 0.78	0.04	0.08
S-VLDL-CE	0.11 ± 0.02	0.12 ± 0.03	0.01 ± 0.005	0.11 ± 0.02	0.11 ± 0.02	0.001 ± 0.01	0.04	0.07
IDL
Concentrations of lipids relative to total lipid concentration in particles of different size
IDL-P (× 10⁻⁴)	0.92 ± 0.2	0.93 ± 0.21	− 0.03 ± 0.06	0.9 ± 0.2	0.85 ± 0.19	− 0.05 ± 0.03	0.81	0.85
IDL-PL_%	27.8 ± 6.21	27.7 ± 6.18	− 0.12 ± 0.09	27.9 ± 6.23	27.9 ± 6.25	0.08 ± 0.11	0.11	0.15
IDL-C_%	61.6 ± 13.8	61.9 ± 13.8	3.37 ± 2.96	61.4 ± 13.7	61.1 ± 13.7	− 0.3 ± 0.43	0.25	0.01
IDL-CE_%	43.7 ± 9.78	44.4 ± 9.93	0.67 ± 0.22	43.7 ± 9.78	43.6 ± 9.75	− 0.12 ± 0.36	0.04	0.04

Values are given in mmol/L. P¹—Delta statistics unadjusted. P²—Delta changes adjusted for changes in weight. Values are reported as mean ± SE. On treatment analysis was performed for all variables. The level of significance was set to p-value < 0.05 after Bonferroni correction. Baseline samples collected at visit 1, post treatment samples were collected at visit 6 (5 weeks of treatment total)
S-LDL-P concentration of small LDL particles, M-LDL-P concentration of medium LDL particles, S-LDL-L total lipids in small LDL, S-LDL-PL phospholipids in small LDL, S-LDL-FC free cholesterol in small LDL, M-LDL-L total lipids in medium LDL, M-LDL-PL phospholipids in medium LDL, S-LDL-PL_% phospholipids to total lipids ratio in small LDL, S-LDL-CE_% cholesterol esters to total lipids ratio in small LDL, S-LDL-FC_% free cholesterol to total lipids ratio in small LDL, M-LDL-PL_% phospholipids to total lipids ratio in medium LDL, M-LDL-CE_% cholesterol esters to total lipids ratio in medium LDL, M-LDL-FC_% free cholesterol to total lipids ratio in medium LDL, L-HDL-C_% total cholesterol to total lipids ratio in large HDL, L-HDL-CE_% cholesterol esters to total lipids ratio in large HDL, XL-HDL-PL_% phospholipids to total lipids ratio in very large HDL, XL-HDL-CE_% cholesterol esters to total lipids ratio in very large HDL, XS-VLDL-PL phospholipids to total lipids ratio in very small VLDL, S-VLDL-C total cholesterol in small VLDL, S-VLDL-CE cholesterol esters in small VLDL, IDL-P concentration of IDL particles, IDL-PL phospholipids in IDL, IDL-C total cholesterol in IDL, IDL-CE cholesterol esters in IDL

Back to article page

ISSN: 1475-2840

Contact us

Submission enquiries: journalsubmissions@springernature.com